“Despite high disease burden, there are no national screening guidelines for multiple myeloma in India”

France-headquartered Sebia, a global leader in specialty diagnostics, is continuing its geographic footprint to better serve its customers.

- By Heejin Roh, Vice President – Commercial Operations, Asia Pacific, Sebia, South Korea

Over the decades, the company has earned worldwide recognition for its pioneering expertise in Multiple Myeloma screening, diagnosis, and monitoring, as well as its leadership in hemoglobinopathies diagnosis. In recent years, Sebia has significantly expanded its portfolio in autoimmunity and infectious disease diagnostics through strategic acquisitions – ORGENTEC in 2021 and ZEUS Scientific in 2022. The company is now all set to strengthen its presence in India, thereby expanding its reach, building talent, and raising awareness. Sebia established its presence in India in 2019, and has achieved consistent double-digit growth year after year. To find out more about the company's growth plans in India, BioSpectrum spoke to Heejin Roh, Vice President – Commercial Operations, Asia Pacific, Sebia. Edited excerpts:

Please share details of the new initiatives to be taken to strengthen the company's presence in India.